Back HCV Populations Children & Adolescents

Sofosbuvir + Ribavirin To Be Studied in Children and Adolescents with Hepatitis C

A Phase 2 clinical trial is now underway to evaluate sofosbuvir (Sovaldi) plus ribavirin for children and adolescents, ages 3-17 years, with hepatitis C virus genotypes 2 or 3. Another study will follow to test the forthcoming sofosbuvir/ledipasir coformulation in pediatric patients.

alt

Read more:

DDW 2014: Sustained Response to Interferon Is Durable in Children with Hepatitis C

Children with hepatitis C treated with interferon-based therapy continued to show undetectable HCV viral load up to 7 years after achieving sustained virological response in the PEDS-C trial, researchers reported at Digestive Disease Week this month in Chicago.

alt

Read more:

FDA Approves Pegasys plus Ribavirin for Children with Chronic Hepatitis C

The U.S. Food and Drug Administration (FDA) has approved pegyalted interferon alfa-2a (brand name Pegasys) plus ribavirin (brand name Copegus) for previously untreated children and adolescents age 5-17 with chronic hepatitis C virus (HCV) infection. alt

Read more: